Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
8
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
8
×
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
8
×
texas top stories
wisconsin blog main
wisconsin top stories
biotech
deals
fda
pfizer
startups
amgen
cancer
clinical trials
johnson & johnson
medicare
abbvie
alzheimer's disease
What
bio
roundup
drug
new
price
alzheimer’s
approval
companies
days
drugs
fallout
fda
news
pharmaceutical
typically
won
acquisitions
airport
amgen
annual
apocalypse
august
bails
beds
biggest
biogen’s
biopharmaceutical
biotech
brand
bridgebio
build
busy
buy
candidates
capital
car
celgene
ceo
class
company’s
Language
unset
Current search:
novartis
×
" eli lilly "
×
" texas blog main "
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines